S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
Log in
NASDAQ:KRYS

Krystal Biotech Competitors

$72.74
+1.09 (+1.52 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$67.99
Now: $72.74
$73.22
50-Day Range
$66.34
MA: $72.49
$85.46
52-Week Range
$33.08
Now: $72.74
$87.29
Volume219,142 shs
Average Volume172,315 shs
Market Capitalization$1.61 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.2

Competitors

Krystal Biotech (NASDAQ:KRYS) Vs. ADPT, VIR, TWST, HALO, KOD, and ALLO

Should you be buying KRYS stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Krystal Biotech, including Adaptive Biotechnologies (ADPT), Vir Biotechnology (VIR), Twist Bioscience (TWST), Halozyme Therapeutics (HALO), Kodiak Sciences (KOD), and Allogene Therapeutics (ALLO).

Adaptive Biotechnologies (NASDAQ:ADPT) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings for Adaptive Biotechnologies and Krystal Biotech, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Adaptive Biotechnologies02402.67
Krystal Biotech00603.00

Adaptive Biotechnologies presently has a consensus price target of $61.40, suggesting a potential upside of 45.39%. Krystal Biotech has a consensus price target of $101.00, suggesting a potential upside of 38.85%. Given Adaptive Biotechnologies' higher probable upside, equities analysts plainly believe Adaptive Biotechnologies is more favorable than Krystal Biotech.

Profitability

This table compares Adaptive Biotechnologies and Krystal Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Adaptive Biotechnologies-132.32%-20.15%-13.09%
Krystal BiotechN/A-10.72%-10.40%

Earnings and Valuation

This table compares Adaptive Biotechnologies and Krystal Biotech's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adaptive Biotechnologies$85.07 million69.11$-68,610,000.00($1.01)-41.81
Krystal BiotechN/AN/A$-19,090,000.00($1.20)-60.62

Krystal Biotech has lower revenue, but higher earnings than Adaptive Biotechnologies. Krystal Biotech is trading at a lower price-to-earnings ratio than Adaptive Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Adaptive Biotechnologies has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500.

Institutional and Insider Ownership

80.8% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 73.1% of Krystal Biotech shares are held by institutional investors. 22.2% of Adaptive Biotechnologies shares are held by company insiders. Comparatively, 27.4% of Krystal Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Krystal Biotech beats Adaptive Biotechnologies on 8 of the 13 factors compared between the two stocks.

Vir Biotechnology (NASDAQ:VIR) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings for Vir Biotechnology and Krystal Biotech, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vir Biotechnology20502.43
Krystal Biotech00603.00

Vir Biotechnology presently has a consensus price target of $63.8571, suggesting a potential upside of 41.34%. Krystal Biotech has a consensus price target of $101.00, suggesting a potential upside of 38.85%. Given Vir Biotechnology's higher probable upside, equities analysts plainly believe Vir Biotechnology is more favorable than Krystal Biotech.

Profitability

This table compares Vir Biotechnology and Krystal Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vir Biotechnology-339.61%-47.11%-39.44%
Krystal BiotechN/A-10.72%-10.40%

Earnings and Valuation

This table compares Vir Biotechnology and Krystal Biotech's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vir Biotechnology$8.09 million713.93$-174,680,000.00($5.76)-7.84
Krystal BiotechN/AN/A$-19,090,000.00($1.20)-60.62

Krystal Biotech has lower revenue, but higher earnings than Vir Biotechnology. Krystal Biotech is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Vir Biotechnology has a beta of -0.99, indicating that its stock price is 199% less volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500.

Institutional and Insider Ownership

54.5% of Vir Biotechnology shares are held by institutional investors. Comparatively, 73.1% of Krystal Biotech shares are held by institutional investors. 37.2% of Vir Biotechnology shares are held by company insiders. Comparatively, 27.4% of Krystal Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Krystal Biotech beats Vir Biotechnology on 9 of the 13 factors compared between the two stocks.

Twist Bioscience (NASDAQ:TWST) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings for Twist Bioscience and Krystal Biotech, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Twist Bioscience11202.25
Krystal Biotech00603.00

Twist Bioscience presently has a consensus price target of $133.3333, suggesting a potential upside of 13.43%. Krystal Biotech has a consensus price target of $101.00, suggesting a potential upside of 38.85%. Given Krystal Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Krystal Biotech is more favorable than Twist Bioscience.

Profitability

This table compares Twist Bioscience and Krystal Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Twist Bioscience-155.31%-44.62%-35.49%
Krystal BiotechN/A-10.72%-10.40%

Earnings and Valuation

This table compares Twist Bioscience and Krystal Biotech's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Twist Bioscience$90.10 million63.47$-139,930,000.00($3.00)-39.18
Krystal BiotechN/AN/A$-19,090,000.00($1.20)-60.62

Krystal Biotech has lower revenue, but higher earnings than Twist Bioscience. Krystal Biotech is trading at a lower price-to-earnings ratio than Twist Bioscience, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Twist Bioscience has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500.

Institutional and Insider Ownership

87.9% of Twist Bioscience shares are held by institutional investors. Comparatively, 73.1% of Krystal Biotech shares are held by institutional investors. 7.0% of Twist Bioscience shares are held by company insiders. Comparatively, 27.4% of Krystal Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Krystal Biotech beats Twist Bioscience on 10 of the 13 factors compared between the two stocks.

Halozyme Therapeutics (NASDAQ:HALO) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends and analyst recommendations.

Institutional and Insider Ownership

98.5% of Halozyme Therapeutics shares are held by institutional investors. Comparatively, 73.1% of Krystal Biotech shares are held by institutional investors. 2.6% of Halozyme Therapeutics shares are held by company insiders. Comparatively, 27.4% of Krystal Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Halozyme Therapeutics and Krystal Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Halozyme Therapeutics10.78%24.29%4.08%
Krystal BiotechN/A-10.72%-10.40%

Analyst Ratings

This is a breakdown of recent ratings for Halozyme Therapeutics and Krystal Biotech, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Halozyme Therapeutics01902.90
Krystal Biotech00603.00

Halozyme Therapeutics presently has a consensus price target of $42.9167, suggesting a potential upside of 4.91%. Krystal Biotech has a consensus price target of $101.00, suggesting a potential upside of 38.85%. Given Krystal Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Krystal Biotech is more favorable than Halozyme Therapeutics.

Earnings and Valuation

This table compares Halozyme Therapeutics and Krystal Biotech's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Halozyme Therapeutics$195.99 million28.24$-72,240,000.00($0.50)-81.82
Krystal BiotechN/AN/A$-19,090,000.00($1.20)-60.62

Krystal Biotech has lower revenue, but higher earnings than Halozyme Therapeutics. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Halozyme Therapeutics has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500.

Summary

Halozyme Therapeutics beats Krystal Biotech on 9 of the 13 factors compared between the two stocks.

Kodiak Sciences (NASDAQ:KOD) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations.

Institutional & Insider Ownership

82.3% of Kodiak Sciences shares are held by institutional investors. Comparatively, 73.1% of Krystal Biotech shares are held by institutional investors. 39.3% of Kodiak Sciences shares are held by company insiders. Comparatively, 27.4% of Krystal Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Kodiak Sciences and Krystal Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kodiak SciencesN/A-32.32%-23.86%
Krystal BiotechN/A-10.72%-10.40%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Kodiak Sciences and Krystal Biotech, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kodiak Sciences17302.18
Krystal Biotech00603.00

Kodiak Sciences presently has a consensus price target of $129.1818, suggesting a potential upside of 7.21%. Krystal Biotech has a consensus price target of $101.00, suggesting a potential upside of 38.85%. Given Krystal Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Krystal Biotech is more favorable than Kodiak Sciences.

Earnings & Valuation

This table compares Kodiak Sciences and Krystal Biotech's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kodiak SciencesN/AN/A$-47,370,000.00($1.25)-96.39
Krystal BiotechN/AN/A$-19,090,000.00($1.20)-60.62

Kodiak Sciences is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Kodiak Sciences has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500.

Summary

Krystal Biotech beats Kodiak Sciences on 8 of the 11 factors compared between the two stocks.

Allogene Therapeutics (NASDAQ:ALLO) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations.

Institutional & Insider Ownership

59.9% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 73.1% of Krystal Biotech shares are held by institutional investors. 31.3% of Allogene Therapeutics shares are held by company insiders. Comparatively, 27.4% of Krystal Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Allogene Therapeutics and Krystal Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Allogene TherapeuticsN/A-27.59%-24.97%
Krystal BiotechN/A-10.72%-10.40%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Allogene Therapeutics and Krystal Biotech, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Allogene Therapeutics031302.81
Krystal Biotech00603.00

Allogene Therapeutics presently has a consensus price target of $52.0833, suggesting a potential upside of 53.19%. Krystal Biotech has a consensus price target of $101.00, suggesting a potential upside of 38.85%. Given Allogene Therapeutics' higher probable upside, research analysts plainly believe Allogene Therapeutics is more favorable than Krystal Biotech.

Earnings & Valuation

This table compares Allogene Therapeutics and Krystal Biotech's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allogene TherapeuticsN/AN/A$-184,590,000.00($1.83)-18.58
Krystal BiotechN/AN/A$-19,090,000.00($1.20)-60.62

Krystal Biotech is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Allogene Therapeutics has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500.

Summary

Krystal Biotech beats Allogene Therapeutics on 6 of the 11 factors compared between the two stocks.


Krystal Biotech Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Adaptive Biotechnologies logo
ADPT
Adaptive Biotechnologies
1.6$42.23+3.4%$5.88 billion$85.07 million-44.45Analyst Downgrade
High Trading Volume
Analyst Revision
News Coverage
Gap Down
Vir Biotechnology logo
VIR
Vir Biotechnology
1.6$45.18+12.2%$5.78 billion$8.09 million-19.14Analyst Report
News Coverage
Gap Up
Twist Bioscience logo
TWST
Twist Bioscience
1.4$117.55+0.8%$5.72 billion$90.10 million-31.35High Trading Volume
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$40.91+1.2%$5.53 billion$195.99 million255.69
Kodiak Sciences logo
KOD
Kodiak Sciences
1.3$120.49+7.3%$5.40 billionN/A-51.94Earnings Announcement
Analyst Report
Analyst Revision
Gap Up
Allogene Therapeutics logo
ALLO
Allogene Therapeutics
1.3$34.00+4.6%$4.78 billionN/A-15.96Analyst Revision
Gap Up
Iovance Biotherapeutics logo
IOVA
Iovance Biotherapeutics
1.7$32.36+1.8%$4.76 billionN/A-16.85Analyst Upgrade
High Trading Volume
China Biologic Products logo
CBPO
China Biologic Products
0.8$117.76+0.3%$4.64 billion$503.70 million32.89Upcoming Earnings
Increase in Short Interest
Beam Therapeutics logo
BEAM
Beam Therapeutics
1.3$72.60+1.2%$4.21 billion$20,000.00-5.17Gap Down
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.6$74.40+6.9%$3.64 billionN/A-42.76Analyst Report
High Trading Volume
Gap Up
RLAY
Relay Therapeutics
1.8$37.39+7.0%$3.36 billionN/A0.00Gap Down
Revolution Medicines logo
RVMD
Revolution Medicines
1.5$45.50+6.7%$3.02 billion$50.04 million0.00Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Up
NantKwest logo
NK
NantKwest
1.1$26.80+3.9%$2.92 billion$40,000.00-37.75Decrease in Short Interest
Gap Down
Editas Medicine logo
EDIT
Editas Medicine
1.4$41.63+3.1%$2.80 billion$20.53 million-23.93Analyst Report
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$63.37+3.7%$2.79 billion$125.57 million-37.06Earnings Announcement
Analyst Report
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$8.88+0.8%$2.49 billion$31.43 million-6.08Analyst Revision
News Coverage
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
0.8$48.18+4.8%$2.14 billionN/A0.00Upcoming Earnings
News Coverage
Gap Up
AlloVir logo
ALVR
AlloVir
1.4$30.52+13.1%$1.99 billionN/A0.00Insider Selling
Gap Down
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$11.15+2.1%$1.98 billion$48.83 million-14.67
Vericel logo
VCEL
Vericel
1.5$42.51+4.9%$1.95 billion$117.85 million-4,251,000.00Analyst Report
Analyst Revision
Gap Up
bluebird bio logo
BLUE
bluebird bio
1.8$28.68+2.6%$1.93 billion$44.67 million-2.61Analyst Report
Gap Up
Scholar Rock logo
SRRK
Scholar Rock
1.3$53.53+5.5%$1.80 billion$20.49 million-22.21Upcoming Earnings
News Coverage
Gap Up
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.1$41.63+6.1%$1.79 billionN/A0.00Upcoming Earnings
News Coverage
Gap Up
Translate Bio logo
TBIO
Translate Bio
1.4$22.23+4.2%$1.65 billion$7.80 million-20.78Upcoming Earnings
Analyst Revision
News Coverage
Gap Up
Ocugen logo
OCGN
Ocugen
1.1$8.74+2.6%$1.64 billionN/A-5.91Analyst Report
Unusual Options Activity
Analyst Revision
Gap Down
Replimune Group logo
REPL
Replimune Group
1.5$35.31+8.5%$1.64 billionN/A-19.95High Trading Volume
News Coverage
Gap Up
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.36+1.1%$1.63 billion$102.43 million-18.93Analyst Downgrade
Analyst Revision
REGENXBIO logo
RGNX
REGENXBIO
1.8$39.93+1.8%$1.49 billion$35.23 million-16.10Earnings Announcement
Analyst Downgrade
Analyst Revision
FMTX
Forma Therapeutics
1.8$33.87+1.3%$1.39 billion$100.56 million0.00Upcoming Earnings
Decrease in Short Interest
News Coverage
Alector logo
ALEC
Alector
1.3$17.07+4.8%$1.36 billion$21.22 million-7.65Analyst Upgrade
News Coverage
Gap Up
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.6$16.07+1.1%$1.34 billionN/A-3.48Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Immunovant logo
IMVT
Immunovant
1.8$13.51+3.2%$1.32 billionN/A-10.47Increase in Short Interest
PCVX
Vaxcyte
1.8$23.76+0.6%$1.21 billionN/A0.00Upcoming Earnings
Insider Selling
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$15.83+3.7%$1.15 billion$356.07 million7.76Analyst Report
Gap Up
Cortexyme logo
CRTX
Cortexyme
1.3$37.99+4.3%$1.12 billionN/A-15.83Earnings Announcement
Gap Up
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$29.36+20.3%$1.11 billionN/A0.00Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Up
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$11.12+1.4%$1.09 billion$250,000.00-8.76Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Mesoblast logo
MESO
Mesoblast
1.4$9.17+0.1%$1.08 billion$32.16 million-10.42Earnings Announcement
Analyst Upgrade
Analyst Revision
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.3$12.56+17.2%$1.02 billionN/A-5.87High Trading Volume
News Coverage
Gap Up
Inhibrx logo
INBX
Inhibrx
1.7$26.39+0.6%$995.22 millionN/A0.00Upcoming Earnings
Gap Down
Passage Bio logo
PASG
Passage Bio
1.9$19.83+2.0%$910.53 millionN/A0.00Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Gap Up
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$25.10+5.5%$906.51 millionN/A-4.15News Coverage
Gap Up
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$18.75+2.7%$879.69 million$69.89 million-4.47Gap Down
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$22.41+3.9%$854.22 millionN/A0.00Gap Up
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.5$24.80+3.0%$828.87 millionN/A-10.25
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$21.11+3.9%$814.93 million$42.74 million-234.56Gap Up
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.13+2.3%$794.02 million$1.12 million-5.18Analyst Upgrade
Gap Up
Cellectis logo
CLLS
Cellectis
1.3$18.19+6.2%$772.82 million$22.99 million-9.68Earnings Announcement
News Coverage
Gap Down
Vaxart logo
VXRT
Vaxart
1.3$6.02+1.7%$708.96 million$9.86 million-10.20Analyst Report
Analyst Revision
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.76+1.5%$657.51 million$2.51 million-4.10Earnings Announcement
Analyst Report
Increase in Short Interest
Analyst Revision
News Coverage
This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.